Repository logo
 
Publication

Guselkumab for the treatment of psoriasis - evidence to date

2019Journal article Open access
Simple item page
dc.contributor.authorNogueira, Miguel
dc.contributor.authorTorres, T.
dc.date.accessioned2020-05-06T23:14:59Z
dc.date.available2020-05-06T23:14:59Z
dc.date.issued2019
dc.description.abstractPsoriasis is a chronic, immune-mediated, inflammatory, and debilitating skin disease with significant impact on patients' quality of life. Its pathogenesis is complex and not yet fully understood. However, the IL-23/IL-17 axis is currently considered the main pathogenic pathway in psoriasis. Guselkumab is a fully human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that binds to the p19 subunit of IL-23. It is the first of its class, already approved by the US Food and Drug Administration (FDA), as well as the European Medicines Agency (EMA) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for either systemic therapy or phototherapy. Several clinical trials have demonstrated potential benefits of guselkumab over other already approved immunomodulators in terms of safety and efficacy. The results of the head-to-head trial ECLIPSE were recently released and are addressed in this review. They contribute to the increasing confidence in guselkumab, demonstrating great potential for long-term treatment of psoriasis. However, further long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationNogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context. 2019;8:212594. Published 2019 Jul 9. doi:10.7573/dic.212594pt_PT
dc.identifier.doi10.7573/dic.212594pt_PT
dc.identifier.issn1740-4398
dc.identifier.urihttp://hdl.handle.net/10400.16/2372
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relation.publisherversionhttps://www.drugsincontext.com/guselkumab-for-the-treatment-of-psoriasis-evidence-to-date/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectantibodiespt_PT
dc.subjectbiological productspt_PT
dc.subjectinterleukin-23pt_PT
dc.subjectmonoclonalpt_PT
dc.subjectpsoriasispt_PT
dc.titleGuselkumab for the treatment of psoriasis - evidence to datept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceEnglandpt_PT
oaire.citation.endPage11pt_PT
oaire.citation.startPage212594pt_PT
oaire.citation.titleDrugs in contextpt_PT
oaire.citation.volume8pt_PT
person.familyNameNogueira
person.familyNameTorres
person.givenNameMiguel
person.givenNameTiago
person.identifier1077508
person.identifier.ciencia-idB01D-0FB4-BD93
person.identifier.ciencia-idFF1B-8834-7AE0
person.identifier.orcid0000-0001-7420-408X
person.identifier.orcid0000-0003-0404-0870
person.identifier.ridC-2604-2014
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication7d343bd1-1095-45e5-b4f8-a7dd49ecc32c
relation.isAuthorOfPublication99c82895-36fa-49af-927a-f75fa1f9bd56
relation.isAuthorOfPublication.latestForDiscovery99c82895-36fa-49af-927a-f75fa1f9bd56

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Guselkumab for the treatment of psoriasis.pdf
Size:
418.6 KB
Format:
Adobe Portable Document Format
Download

Collections

SD - Artigos publicados em revistas indexadas na Medline/Pubmed